Are serum immunoglobulin concentrations a predictive biomarker of response to anti-IL5/IL5Rα therapies? - 17/06/22

Abstract |
Background |
Approval of biologics has recently revolutionized T2 severe asthma management. However, predictive biomarkers remain highly needed to improve patient's selection.
Objective |
This study aims to determine whether serum immunoglobulins (Igs) levels might be predictive biomarkers of response to anti-interleukin-5 (IL5)/IL5Rα therapies.
Methods |
Severe asthma patients eligible for mepolizumab or benralizumab were included herein. Serum immunoglobulin quantification was performed at baseline before mepolizumab or benralizumab initiation. After a 6-month treatment of mepolizumab or benralizumab, patients presented a second serum immunoglobulin quantification. The treatment response was evaluated by the GETE (Global Evaluation of Treatment Effectiveness) score at 6 months.
Results |
A total of 50 patients were included. Median age was 56 [IQR 48.8–65.3] and 50% were females. Compared to baseline, a significant increase in IgG was observed at 6 months (9.2 [7.8–10.2] g/l vs 10.1 [8.8–11.1] g/l, p = 0.04). The area under the ROC curve was 0.58 [95%IC 0.40–0.77] for blood eosinophil count (p = 0.37), 0.75 [95%IC: 0.58–0.92] for serum IgG concentration (p = 0.009) for predicting the treatment response. According to the Youden index, serum IgG concentration ≥ 9.2 g/l predicts the response to anti-IL5 therapies with a sensitivity of 76.9% and a specificity of 75.7%.
Conclusion |
Baseline serum IgG concentrations may be a useful tool to predict the response to anti-IL5/IL5Rα therapies but should be confirmed in larger clinical trials. Interestingly, anti-IL5/IL5Rα therapies are associated with a significant increase in serum IgG concentrations at 6 months.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, Mepolizumab, Benralizumab, IgG, Biomarkers
Abbreviations : ACT, FEV1, FVC, GETE, IL5, IL5R, ROC
Plan
Vol 81
Article 100882- mai 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?